Eton Snags U.S. Rights to LIBERVANT Buccal Film, Adding Neurology Growth Driver
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals licensed exclusive U.S. rights to LIBERVANT, Aquestive's diazepam buccal film for seizure clusters, adding a neurology product to its rare disease portfolio. The deal, entered into on October 13, 2026, includes a $10 million upfront fee, up to $47.5 million in regulatory and commercial milestones, and mid-teens royalties on U.S. net sales. Eton will pay Aquestive $10 million upon first commercial sale, reduced to $5 million if full FDA approval permitting commercial sale for ages 2–5 has not been received, and $2.5 million upon FDA approval for ages 6–11. Up to $35 million of commercial milestones are tied to achieving certain annual net sales levels in the United States. The agreement includes a supply deal with Aquestive, which will serve as the exclusive manufacturer and supplier of the product, with an initial term of 20 years and automatic three-year extensions. LIBERVANT has issued patent protection extending into 2038, with additional patent applications pending. Eton plans to establish a dedicated neurology team supported by its existing commercial infrastructure. The deal targets a U.S. seizure rescue market exceeding $450 million annually, with commercial launch anticipated April 2027 pending final FDA approval. LIBERVANT already has tentative approval for ages 2-5 and 12+, with full approval for 12+ expected January 10, 2027 after VALTOCO's orphan exclusivity expires, and a PDUFA date of March 29, 2027 for label expansion to ages 6-11. This follows Eton's strong Q2 2026 results (revenue up 99% YoY) and recent product launches, reinforcing its acquisition-driven growth strategy. Watch for FDA decisions in January and March 2027 as key milestones for the launch timeline.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Eton paid Aquestive a $10 million upfront fee, with up to $47.5 million in regulatory and commercial milestones and mid-teens royalties on U.S. net sales.
- Milestone Payments — Eton will pay Aquestive $10 million upon first commercial sale, reduced to $5 million if full FDA approval permitting commercial sale for ages 2–5 has not been received. Eton will pay $2.5 million upon FDA approval for ages 6–11. Up to $35 million of commercial milestones are tied to achieving certain annual net sales levels.
- Supply Agreement — Aquestive will serve as the exclusive manufacturer and supplier of the product, subject to specified exceptions. The initial term is 20 years, with automatic three-year extensions unless either party notifies the other at least two years prior to the end of the term.
- Patent Protection — LIBERVANT has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark Office.
- Commercial Plans — Eton plans to establish a dedicated neurology team supported by its existing commercial infrastructure.
All 8 details
- Eton will pay Aquestive $10 million upon first commercial sale, reduced to $5 million if full FDA approval permitting commercial sale for ages 2–5 has not been received.
- Eton will pay Aquestive $2.5 million upon approval by the FDA of the Product for patients ages 6–11.
- Up to $35 million of commercial milestones tied to Product’s achievement of certain annual net sales levels in the United States.
- Aquestive will serve as the exclusive manufacturer and supplier of the Product, subject to specified exceptions.
- The Supply Agreement provides for an initial term of 20 years, with automatic extension for succeeding three-year periods unless either party notifies the other of its desire not to renew at least two years prior to the end of the initial term or any succeeding term.
- LIBERVANT has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark Office.
- Eton plans to establish a dedicated neurology team supported by its existing commercial infrastructure.
- Eton entered into the license agreement on October 13, 2026.
At the time of this announcement, ETON was trading at $55.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $14.27 to $66.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.